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Abstract Mesenchymal stem cells (MSCs) are an impor-
tant cell source for tissue engineering (TE) and cell ther-
apies for several reasons including ease of isolation from
multiple tissues, uncomplicated ex vivo culture, ability to
self-renew and differentiate into numerous cell types,
MSC/immune cell interactions and pro-reparative proper-
ties. Current MSC therapies involve administration via
intravenous (I.V.) injection. However, this can result in
MSC entrapment and failure to target injured site. In TE,
artificial 3D constructs are being investigated as strategies
for direct delivery of MSCs to a target area. However, these
constructs have numerous limitations including lack of cell
infiltration, poor cell functionality and limited diffusion of
nutrients and oxygen through the scaffolds. We are inves-
tigating the jetting methodology bio-electrospraying (BES)
as an alternative strategy for MSCs delivery in vivo that
may overcome obstacles associated with I.V. injections and
scaffold transplantation. For BES in vivo, low voltages,
stable jetting and a single needle configuration are highly
desirable. A commercially available electrospray apparatus
Spraybase was used to electrospray mouse bone marrow-
derived MSCs (mBMSCs) at low voltages (* 3–6 kV)
in vitro. Stable jetting conditions with a single needle at
these low voltages were established by employing a ring-
shape electrode for potential difference, specific culture
medium and the use of high mBMSCs numbers to over-
come viscosity difficulties. The viability and functionality
of the mBMSCs following BES was determined by ana-
lysing expression of specific surface markers, multilineage
differentiation, suppression of T- cell activation and pro-
reparative capabilities. We show that mBMSCs post-BES
functioned similarly to non-bio-electrospray (non-BES)
control mBMSCs for all parameters examined. This
methodology may subsequently enable targeted delivery of
MSCs to an injury site in vivo and potentially avoid the
complications associated with MSCs entrapment and the
limitations associated with artificial scaffolds.
Keywords Bio-electrospraying  Mesenchymal stromal/
stem cells  Cell delivery  Tissue engineering  Cell
therapies  Bone marrow stem cells
1 Introduction
Mesenchymal stem cells, also called mesenchymal stromal
cells (MSCs) are an important cell source for tissue engi-
neering (TE) and cell therapies. They are readily accessible
from multiple tissues, including bone marrow and adipose
tissue. MSCs have ability to self-renew and differentiate
into numerous cell types including; osteoblasts, chondro-
cytes, myocytes, adipocytes and fibroblasts [1]. These cells
are also easily isolated and cultured ex vivo. Human MSCs
(hMSCs) can be isolated from the bone marrow of patients
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and as such are a clinically viable cell source. Importantly,
hMSCs can be directly implanted back to injured regions in
the same patient, significantly reducing the possibility of
transplant rejection [2]. In addition to this, MSCs are also
favoured for therapies due to their interactions with
immune cells and their expression of low levels of major
histocompatibility complex (MHC) class I, and no MHC
class II which allows them to evade allogeneic reactions
and natural killer cell-mediated killing [3].
Patient MSC therapy currently involves administration
through intravenous (I.V.) injection. This allows cells to
move through the blood stream to any site in the body,
regardless of the intended target site and the efficiency of
targeting the injury site can be low. Furthermore, a well-
documented phenomenon, MSC entrapment, can occur
after MSCs are administrated by I.V. injection whereby
MSCs remain in the lungs and liver of rodents [4]. This has
also been reported in patient trials [5–10]. The risk of acute
or chronic adverse side effects from entrapment of cells in
the lungs or liver means that careful patient monitoring is
essential.
In tissue engineering, conventional strategies for
administrating MSCs to a target area include the fabrica-
tion of artificial 3D constructs. These constructs should
mimic the structure and function of the native tissue while
facilitating regeneration in vivo [11]. However, to date, the
synthetic environment of these 3D constructs has numerous
limitations including lack of cell infiltration through the
scaffold, limited diffusion of oxygen and nutrients and
failure of desired cell functions. This is generally due to
small pore sizes, the chemistry of the materials used to
fabricate the scaffolds and the surface texture of the scaf-
folds. Numerous reviews have discussed the wide range of
studies carried out to address these problems, however the
fabrication of successful in vivo 3D constructs remains
challenging [12–17].
In 2006, the Jayasinghe group was the first to report the
adaptation of a well-established physics phenomenon
called electrospraying for cell delivery and TE applica-
tions. Briefly, electrospraying is a jetting methodology
whereby tiny quantities of electrical charge are applied to a
fluid as it passes through an emitter resulting in the for-
mation of a spray jet. This spray is finer, more controllable
and significantly faster than aerosol [18]. By electro-
spraying a solution of living cells with no apparent dele-
terious effect on the cells, the group developed the process
known as ‘bio-electrospraying’ (BES) [19–22]. Since then,
a range of cell types have been reported as being suc-
cessfully electrosprayed including primary cardiac cells
(PCCs), mouse hematopoietic stem cells (mHSCs), mouse
bone marrow derived stem cells (mBMSCs), embryonic
stem cells (ESCs) and human adipose derived stem cells
(hASCs) [23–28]. In establishing stable jetting conditions
for BES, parameters such as potential difference, flow rate
of cell/culture medium solution and culture medium
properties are important [29–31]. Potential difference
refers to the difference in potential between the emitter and
the ground electrode. Three types of ground electrodes
have been employed in studies aiming to achieve
stable cone-jets: ring, plate and point-shaped electrodes.
The properties of the culture medium, including viscosity,
electrical conductivity, surface tension and density, as well
as the consistency of the flow rate of culture medium
through the needle are also critical parameters for gener-
ation of stable jetting conditions [32]. Viscosity and elec-
trical conductivity are two significant parameters that can
affect jetting stability. Low viscosity can lead to unsta-
ble jetting. Previous studies addressed the problem of low
viscosity by electrospraying solutions containing high
numbers of cells, which results in increased viscosity levels
[24, 28]. However, this also results in increasing already
high conductivity levels, which leads to unstable jetting
with existing electrospray apparatuses. To address this,
groups have used coaxial needles and a sheath gas to
protect the cells and prevent sparking at the high voltages
that are necessary to produce stable jets. This configuration
is not compatible with in vivo applications. Efforts to use a
single needle rather than a coaxial needle have not been
successful to date [32].
We propose that BES may be an important strategy for
delivery of MSCs to specific injury sites in vivo. However,
studies carried out to date are not compatible with in vivo
use because of the high voltages required to generate
stable cone jets. High voltages are not desirable clinically
and lead to MSC death and loss of function. While other
groups have used electrospray apparatuses assembled in-
house, we used Spraybase, a commercially available
electrospray instrument which facilitates consistent elec-
trospraying and requires lower voltages than in-house
assemblies. We also optimised specific parameters to
achieve a stable BES using a lower and a single needle
rather than higher voltages, a coaxial needle and a sheath
gas. Furthermore, previous studies have not comprehen-
sively examined the functionality of MSCs post-BES. Here
we have examined tri-lineage differentiation, expression of
specific surface markers associated with MSCs, suppres-
sion of T- cell activation and pro-reparative properties of
BES, and we demonstrate that mBMSCs behaved similarly
to their non-bio-electrosprayed (non-BES) counterparts in
all biological aspects, potentially providing an alternative
delivery method for MSC therapies, and tissue engineering
and regenerative medicine purposes.
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2 Materials and Methods
2.1 Animals and Cells
Six-to-eight week old female BALB/c mice and C57/BL6
mice (Charles River Lab Manston Rd, Margate, UK) were
used for experiments under the guidelines with ethical
approval received from the ethics committee of Maynooth
University (Ref: BSRESC-2012-015). The A549 human
lung adenocarcinoma cell line and human bronchial
epithelial cell line (BEAS 2B cells) were obtained from the
European Collection of Cell Cultures.
2.1.1 Isolation and Culture of Murine Bone Marrow-
Derived MSC
Murine BMSCs were isolated and expanded using modi-
fications of methods previously described [33, 34]. Modi-
fications included flushing out bone marrow using
specialised mesenchymal stem cell medium ‘Mesenchym-
stem’ (GE Healthcare Life Sciences, Buckinghamshire,
UK). Isolated cells (6.0–6.5 9 107) were suspended in
Mesenchymstem containing 10 lg/ml penicillin/strepto-
mycin (P/S) (Gibco, Paisley, UK) in T75 flasks and incu-
bated in hypoxic conditions (5% O2). Non-adherent cells
were removed after 3 h. The flasks were washed with
sterile PBS after 24 and 48 h and incubated for 3 weeks
until colonies of fibroblast-like cells appeared. Cells were
passaged by trypsinisation with 0.2 mM trypsin/1 mM
EDTA (Invitrogen-Gibco) for 2 min at 37 C. Cells were
centrifuged (4009g, 5 min) and re-seeded at 5–6 9 106
cells in T75 (passage 1). Passage 2 cells were cultured in
mesenchymstem media, 10 lg/ml penicillin/streptomycin
and 1 ng/ml murine basic fibroblast growth factor (bFGF)
(Peprotech, Rocky Hill, NJ, US). Passage 3 cells were
cultured in expansion medium (ca-MEM medium) con-
sisting of Minimum Essential Medium Alpha medium
(Gibco) supplemented with 10% (v/v) heat inactivated fetal
bovine serum (FBS) (Gibco), 10% (v/v) equine serum
(Hyclone laboratories, Logan, UT), 10 lg/ml penicillin/
streptomycin, 10 lg/ml L-glutamine (Gibco) and 1 ng/ml
murine bFGF in T-175 flasks. Cells were maintained in
either hypoxic (5% O2) (passage 1–3) or normoxic (21%
O2) (passage 4–10) conditions. Surface marker expression,
multilineage differentiation and T cell suppression assay
was carried out as described below to ensure that mBMSCs
were not contaminated with hematopoietic or other cell
contaminants, and that cells retained differentiation
capacity as previously described [34]. Cells were used
between passages 3–10.
2.2 Bio-Electrospray Apparatus and Optimization
The ‘Generation 1’ BES instrument was purchased from
Avectas (Dublin, Ireland) and consisted of a voltage sup-
ply, double syringe pump, a single extrusion needle
(30 gauge) configuration, lab jack, camera, laser and ring-
shaped ground electrode. Working in a dark, non-sterile
environment, mBMSCs ranging from 1 9 106 and
6 9 106 cells/ml, suspended in ca-MEM medium, were
delivered using the syringe pump via a 1 ml syringe to the
extrusion needle. The conductivity of the mBMSCs/ca-
MEM medium solution was measured as 22.18 mS/cm
using a conductivity metre (Mettler Toledo, Ireland). An
electric field was applied to the needle to draw the cells
into jets and deposit them in droplets into 6-well or 24-well
sterile tissue culture plates. Sprays were illuminated with
the laser and photographs were taken with the camera 1
frame/sec over 5 s to determine when a continuous,
stable Taylor cone was achieved. Voltages of 1, 2, 3, 4, 5
and 6 kV were tested and distances and flow rates were
varied. It was established the optimum conditions for
electrospraying mBMSCs with this device used voltages
between 3 and 6 kV, which varied depending on the rela-
tively humidity (RH), flow rate at 5 ll/min and potential
distance of 22 mm. 24-well plates were used to collect
cells for studies examining mBMSCs viability and pro-
reparative properties while mBMSCs were collected in
6-well plates for differentiation and immunomodulatory
studies.
2.3 Measurement of Consistency of Bio-
Electrospray Delivery
A suspension of 3.5 9 106 mBMSCs in 300 ll ca-MEM
medium was bio-electrosprayed at a flow rate of 5 ll/min.
Three 100 ll fractions were collected sequentially in three
separate wells of a 24 well plate. These cells were imme-
diately harvested and counted using a haemocytometer
(Sigma-Aldrich) and Olympus CK40 Light Microscope
(Olympus, Germany).
2.4 Viability of mBMSCs
On three separate days, 1 9 106 mBMSCs/ml were elec-
trosprayed into three wells. The cells were immediately
harvested from the wells and counted using a haemocy-
tometer and ethidium bromide/acridine orange (EB/AO)
viable staining. In addition, 1 9 106 pipette mBMSCs,
which represent non-BES cells, and BES mBMSCs were
harvested and suspended in 500 ll PBS supplemented with
1% (v/v) FBS (FACS buffer). Furthermore, 5 ll of
7-amino-actinomycin D (7-AAD) Staining Solution (e-
Bioscience, San Diego, CA, US) was added, the cells were
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incubated for 15 min at 4 C and then analysed by flow
cytometry (FACS Accuri, California, USA) using CFlow-
Plus software (BD Biosciences, Oxford, UK) on day 1, 7,
14.
2.5 Surface Marker Detection on mBMSCs
Both pipette and BES mBMSCs were harvested, washed in
sterile PBS and suspended in FACS buffer to yield
approximately 1 9 105 cells/4 ml polypropylene FACS
tubes (Falcon, BD Biosciences). Fluorochrome conjugated
antibodies (Table 1) and their isotype controls were incu-
bated with cells for 15 min at 4 C. Cells were then washed
in 2 ml FACS buffer, vortexed and centrifuged (3009g,
5 min). The supernatant was removed and cells were re-
suspended in 200 ml FACS buffer. Cells were then anal-
ysed by flow cytometry.
2.6 Tri-Linage Differentiation of mBMSCs
2.6.1 Osteogenic Differentiation of mBMSCs
mBMSCs were both pipetted and BES at a density 5 9 104
cells/ml into a 6-well plate and incubated at 37 C, 5%
CO2. Once confluent, typically after 3–4 days, cells were
incubated for 21 days in osteogenic differentiation medium
containing a-MEM, 1 mM dexamethasone (Sigma-
Aldrich, Dublin, Ireland), 20 mM b-glycerolphosphate
(Sigma-Aldrich), 50 lM L-ascorbic acid-2-phosphate
(Sigma-Aldrich), 50 ng/ml L-thyroxine sodium pentahy-
drate (Sigma-Aldrich). The medium was then removed and
cells were fixed in 10% (v/v) neutral buffered formalin for
20 min at room temperature. After several washes in PBS,
cells were incubated for 20 min in 1 ml of 1% (w/v)
Alizarin Red S Stain. Cells were then washed with dH2O.
For visualisation, 1 ml of dH2O was added to each well and
cells were examined under the microscope.
2.6.2 Adipogenic Differentiation of mBMSCs
Pipette and BES mBMSCs were seeded at a density
5 9 104 cells/ml into a 6-well plate. Once confluent, cells
were incubated for 21 days in adipogenic differentiation
medium consisting of a-MEM, 5.0 lg/ml insulin in 0.1 N
acetic acid (Sigma-Aldrich), 50 lM indomethacin (Sigma-
Aldrich), 1 lM dexamethasone (Sigma-Aldrich), 0.5 lM
3-isobutyl-1-methylxanthine (IBMx) in methanol (Sigma-
Aldrich). Cells were fixed in 10% neutral buffered formalin
for 20 min at room temperature, washed in PBS, stained
with 1 ml of 0.5% (w/v) Oil Red O Isopropanol fat dif-
ferentiation stain and examined using a microscope.
2.6.3 Chondrogenic Differentiation of mBMSCs
Pipette and BES mBMSCs were seeded at a density
2 9 105 cells/ml into a 24-well plate, immediately har-
vested and centrifuged (3009g, 5 min) in a 15 ml
polypropylene tube. The pellet was cultured in 500 ll
chondrogenic medium and incubated in normoxic incuba-
tor. The chondrogenic medium consisted of a-MEM,
100 nM dexamethasone, 50 lg/ml ascorbic-acid-2-phos-
phate (Sigma, Dublin,Ireland), 40 lg/ml proline (Gibco),
1 mM sodium pyruvate (1:99) ITS ? supplement (Gibco),
10 ng/ml TGF-b3(Peprotech). Fresh medium was added
every 3–4 days for 21 days, after which the pellet was
washed with Dulbecco’s PBS. Total RNA from cells
growing in a 15 ml tube was isolated using TRIZOL
Reagent (Invitrogen-Life Technologies). RNA was DNase
Table 1 Antibodies for flow
cytometry
Application Antibody Fluorochrome Isotype Supplier
Flow cytometry CD 11b FITC Rat IgG2b e-Bioscience
CD 34 FITC Rat IgG2a e-Bioscience
CD 44 PE Rat IgG2b e-Bioscience
CD 45 PE Rat IgG2b e-Bioscience
CD 73 PE Rat IgG1 e-Bioscience
CD 86 PE Rat IgG2a e-Bioscience
CD 90.2 FITC Rat IgG2b e-Bioscience
CD 105 PE Rat IgG2a e-Bioscience
CD 106 FITC Rat IgG2a e-Bioscience
CD 117 FITC Rat IgG2b e-Bioscience
Sca-1 PE Rat IgG2b e-Bioscience
MHC class l FITC Mouse IgG2a e-Bioscience
MHC class ll PE Rat IgG2b e-Bioscience
Table of fluorochrome conjugated antibodies and isotype controls used for detecting surface markers for
mBMSCs characterisation
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treated (Invitrogen-Life Technologies) and reverse tran-
scribed using Superscript III Reverse Transcriptase (In-
vitrogen-Life Technologies). PCR products were separated
by agarose gel electrophoresis and visualised using GelRed
Nucleic Acid Stain (Biotium, Cambridge, UK) using
Quantity One densitometry software version 4.4.1 (Biorad,
Hemel Hempstead, Hertfordshire, UK). Target transcripts
were amplified using primers for Collagen IIa and Aggre-
can (Sigma) and GAPDH (Eurofins) (Table 2).
2.7 T-Cell Suppression Assay
Both pipette and BES mBMSCs were seeded at 1.5 9 104/
ml in a 96-well plate in 100 ll of ca-MEM and incubated
overnight. The next day, splenocytes were isolated from
the spleens of two MHC mismatched mice. BALB/c mice
splenocytes’ were represented as Donor 1 (D1) and C57/
BL6 mice as Donor 2 (D2). The suspended pellets were
stained with carboxyfluorescein diacetate succinimidyl
ester (CFSE) Proliferation Kit (CellTraceTM, Life Tech-
nologies, Dublin, Ireland) using a previously described
method [35]. Briefly, splenocyte pellets suspended in 1 ml
RPMI 1640 (Invitrogen-Gibco) supplemented with 5%
FBS were placed in 15 ml polypropylene tubes and laid
horizontally. PBS was pipetted at 110 ll at the top of the
15 ml tube, ensuring the PBS and the pellet did not mix.
Following this, 1.1 ll of 5 mM CFSE (CellTraceTM) was
added to the PBS. The solutions were then quickly inverted
and vortexed to mix the cells and CFSE together. The tube
was covered with foil and incubated for 5 min at room
temp. Furthermore, 10 ml 20 C PBS containing 5% FBS
was added and centrifuged (3009g, 5 min). The pellets
were then suspended in 1 ml RPMI 1640 supplemented
with 10% (v/v) FBS, 10 lg/ml penicillin/streptomycin,
10 lg/ml L-glutamine. Splenocytes were seeded at
2 9 105/well and incubated for 72 h. On day 5, spleno-
cytes were transferred to 96 well V-bottom plates (Corning
Inc., NY, USA), centrifuged (9509g, 5 min) and super-
natant was discarded. Cells were washed with 100 ll
FACS buffer, centrifuged (9509g, 5 min) and supernatant
was discarded. Then 0.3 ll CD3-APC (e-Bioscience),
0.3 ll 7-AAD and 2.4 ll FACS buffer were added to each
well and plates were incubated at 4 C for 15 min. Cells
were washed again with 200 ll FACS buffer, centrifuged
(9509g, 5 min) and supernatant was removed. 100 ll
FACS buffer was added to each well and splenocytes were
analysed by flow cytometry.
2.8 Scratch Assay (Wound Closure Assay)
A549 or BEAS-2B cells were seeded at 5 9 104 cells/well
in culture medium (Dubeco’s Modified Eagles Basal
Medium (DMEM-F12) (Gibco, Paisley, UK), 5% FBS,
2 mM L-Glutamine) into the lower chambers of a
24-transwell plate. After 24 h, a P200 pipette tip was used
to scratch a line through the confluent monolayer of A549
cells in each well to make a wound. Following this, either
pipette mBMSCs, BES mBMSCs or control media was
added to the transwell inserts. After 24 h, the A549 or
BEAS-2B cells were fixed with 500 ll of 10% formalin at
room temp for 20 min and then stained with 1% crystal
violet dye (Sigma, Dublin, Ireland) at room temp for
20 min. Plates were washed five times with PBS and cells
were examined using a microscope. The width of the
wound was measured at the top, middle and bottom of each
well and an average width was determined for each well,
demonstrating the width of wound closure obtained.
2.9 Statistical Analyses
Statistical analysis was performed using GraphPad
PrismTM software (GraphPad, San Diego, CA). Paired
t-test was used when statistical analysis was required
between two experimental groups. One way ANOVA was
used to test for statistical significance of differences when
multiple experimental groups were compared with post hoc
tukey. Data are presented as the ± standard error of the
mean (SEM). P-values of p\ 0.05 (*), p\ 0.01 (**) or
p\ 0.001 (***) were considered statistically significant.
Table 2 Primers
Primer Forward 50–30 Reverse 30–50 Size (bp) Anneal temp. (C)
Collagen IIa GCGATGACATTATCTGTGAAG TATCTCTGATATCTCCAGGTTC 150 58
Aggrecan CTACCTTGGAGATCCAGAAC TGGAACACAATACCTTTCAC 121 58
GAPDH GCACAGTCAAGGCCGAGAAT GCCTTCTCCATGGTGGTGAA 151 58
Table of primers for chondrocyte differentiation
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3 Results
3.1 Optimization of Bio-Electrospray Parameters
Previous studies have examined various parameters for
successful BES of MSCs. The viscosity and electrical
conductivity of the culture medium in which primary cells
are sprayed have been shown to be important parameters
that affect the ability to generate a stable jet. In previous
studies, high cell numbers have been used to increase
viscosity. However, this has resulted in high conductivity
which in turn necessitates the use of voltages up to 15 kV
to generate stable jets. To avoid sparking at these voltage
levels, a coaxial needle/sheath gas emitter configuration
has been used. In the present study, we used a commer-
cially available electrospray apparatus to optimise a range
of parameters to develop a configuration that would allow
successful generation of stable jets of mBMSCs at low
voltages.
It is unclear from previous reports what exact apparatus
was used for electrospray because the equipment appears
usually to be built and assembled in-house. This also makes
it difficult to reproduce results between labs. We used the
newly commercially available Spraybase Generation 1
instrument (Fig. 1a). We could achieve lower voltages with
this instrument than with our previous in-house apparatus
and we assume that this is due to the design of the
Spraybase instrument. Odenwalder et al. [32] used a ring-
shaped ground electrode which they placed into the culture
well. The electrospray is attracted to the ground electrode
and this shape is likely to encourage the cells to cover the
bottom of the well. We used copper wire to form a similar
ring-shaped electrode (Fig. 1b).
We discovered that cell suspensions of 1 9 106 cell/ml
in ca-MEM medium, a ring-shaped ground electrode, a
single needle configuration and the purpose-built power
supply contained within Spraybase contributed to the
successful generation of stable sprays/jets of mBMSCs at
low voltages. A flowrate of 5 ll/min with voltages ranging
Fig. 1 ‘‘Generation 1’’
Spraybase  developed by
Avectas. a Device consists of a
syringe pump which delivers
cell suspensions to a single
extrusion needle, charged by
IEC standard approved power
supply unit, with laser and
camera. b Ground ring electrode
in well of 24-well plate
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from 3 to 6 kV, depending on the RH, and a 30-gauge
single needle configuration was subsequently used
throughout our experiments. Voltages above 6 kV caused
the spray to become increasingly unstable, triggering an
output of intermittent spurts of cells. Only a few droplets, if
any, were directed towards the tissue culture plate. A jet
spray was observed when higher cell numbers of 3 9 106/
ml were used whereas and a plume spray was observed
with lower cells numbers of 1 9 106/ml as seen in Fig. 2a,
b. An unstable spray was observed at voltages above 6 kV
(Fig. 2c).
3.2 Distribution of mBMSCs During Bio-
Electrospray
We next examined whether the mBMSCs were being
delivered into the collecting tissue culture plate in even
numbers during a spray period or whether cells were
accumulating near the front or the back of the flow and
hence arriving at an uneven rate into the collecting plate.
This was achieved by collecting sequential fractions of
cells as they emerged from the emitter. A suspension of
mBMSCs at 3.5 9 106 cell/300 ll in ca-MEM medium
was sprayed at a flow rate of 5 ll/min and 100 ll. Three
sequential fractions were collected in individual wells of a
24 well plate. Theoretically, if the flow of cells was con-
tinuous, 1.166 9 106 cells should be present in each frac-
tion. It was found that over three separate experiments,
fractions 1, 2 and 3 contained 90 ± 0.04, 87 ± 0.1 and
90 ± 0.02% of the theoretical value (Fig. 3). This indicates
Fig. 2 Electrosprays and jets.
mBMSCs suspended in ca-
MEM were BES at different
voltages to get desired jet/spray.
a, b show both jet and spray
respectively. Optimum
parameters include; 3–6 kV
(depending on RH), flowrate of
5 ll/min, potential distance
22 mm, internal diameter of
syringe 1.457 mm and 30-gauge
extrusion needle.
c Demonstrates an inconsistent
and unstable BES intermittingly
spurting out cells from the
needle at 10 kV. Pictures were
taken 1 frame/sec for 5 frames
Fig. 3 Graph of distributed Bio-electrosprayed mBMSCs by frac-
tions. Using optimum parameters, 3.5 9 106/300 ll mBMSCs were
electrosprayed into 3 separate wells of a 24 well plate (n-3). Using 3
fractions, cells were distributed evenly/100 ll. These cells were then
counted immediately post BES. The graph represents the number of
cells counted in each well/100 ll, demonstrating a continuous and
even amount of cell suspension is distributed from the needle across
the wells
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that the cells were being delivered in even numbers during
the spray period.
3.3 Viability of Bio-Electrosprayed mBMSCs
Previous studies have shown that strong external electric
fields, from 0.5 to 2.0 kV/cm, can induce pore formation
and cell membrane damage, leading to high levels of cell
death [36–39]. Chen et al, further demonstrated that high
voltages induce internal thermal damage to cells [39]. The
viability of mBMSCs following BES using the optimized
parameters was determined. It was found that approxi-
mately 80 9 104 ± 1.7, 82 9 104 ± 1.9 and
80 9 104 ± 0.7% were viable mBMSCs when counted
post BES. This indicated a high volume of mBMSCs were
electrospraying into the wells (n-3). To further prove
mBMSCs viability, a known dye exclusion assay (7-ADD)
was carried out on both non-BES and BES cells. Analysis
at day 1, 7, and 14 demonstrated that approximately
90 ± 0.9%, 89 ± 2.9%, 90 ± 0.4% cells remained viable
for non-BES, whereby 80 ± 3.9%, 80 ± 2.6%, 79 ± 1.2%
cells remained viable following BES (n-3). It was also
shown that there was no significance between electro-
sprayed cells 80 ± 1.3% and non-BES mBMSCs
90 ± 1.5% as demonstrated in Fig. 4a–c.
Fig. 4 Graph of Bio-
Electrosprayed mBMSCs
Viability. Viability of BES
mBMSCs was detected using
both a EB/OA and b 7-AAD
viability staining solutions. Both
stains are dye exclusion assays
which identify nonviable cells
by light microscope or by flow
cytometry respectively. c Graph
represents the % of viable BES
mBMSC and non-BES (n-3)
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3.4 Characterization of mBMSCs Pre- and Post-
BES
In order to confirm the phenotype of the mBMSCs popu-
lation used in these studies, marker expression was exam-
ined for both non-BES and BES cells. Expression of
thirteen characteristic MSC cell surface markers, as
described by the International Society for Cellular Therapy
(ISCT), were examined using flow cytometry (Table 3)
[40]. Expression of Sca-1, CD44, CD73, CD90, CD105,
CD106 with minimum MHC Class I expression, and the
absence of CD11b, the lymphocyte maker CD34,
haematopoietic marker CD45, co-stimulatory marker
CD86, MHC Class II, and CD117 demonstrated the
expected mBMSCs phenotype for both non-BES and BES
cells. This was illustrated when the cell surface marker
represented by the red line using flow cytometry, ‘‘shifted’’
to the right of its corresponding isotype or control (black
line), indicating a positive expression was determined.
However, if the red line remained either within the black
line or ‘‘shifted’’ to the left, this indicated a negative
expression and thus the absence of the marker. Comparing
the non-BES and BES mBMSCs percentage surface marker
shift, the results demonstrated that the BES process did not
alter cell surface marker expression in the electrosprayed
cells shown in Fig. 5a and b.
3.5 Multilineage Differentiation of Bio-
Electrosprayed mBMSCs
Having demonstrated that acceptable levels of cell viability
were attained with our optimised BES protocol, we then
examined the effect of the protocol on MSC function.
Three key characteristics were analysed: multilineage dif-
ferentiation ability, suppression of T-cell proliferation and
pro-reparative capability. By definition, MSCs must show
multilineage differentiation capability, for example
towards osteoblast, adipocyte and chondrocyte lineages [1].
We therefore examined the ability of mBMSCs to differ-
entiate towards osteoblast, adipocyte and chondrocyte lin-
eages. The ability of differentiation capability of mBMSCs
that had been subjected to BES was also examined to
determine if the electrospray process adversely affected
this capability.
For osteoblast, adipocyte and chondrocyte differentia-
tion, cells were cultured under specific differentiation
conditions for 21 days. Cells were then analysed for
expression of differentiation-specific features. Osteoblasts
were stained with Alizarin Red S Stain to visualise calcium
deposits, adipocytes were stained with Oil Red O Iso-
propanol to visualise fat deposits and RNA was extracted
from chondrocytes for detection of expression of markers
genes. Differentiation for the three linages was observed
either by micrographs (osteoblasts and adipocytes) or by
marker expression as seen in chondrocyte differentiation,
for both non-BES mBMSCs and BES mBMSCs (Fig. 6).
Similar patterns of calcium and fat deposits were present in
non-BES mBMSCs and BES mBMSCs differentiated cells.
Similarly, expression of aggrecan and collagen IIa was
increased in both non-BES mBMSCs and BES mBMSCs.
However, due to a small percentage of cell loss (approx.
20%) possibly from cell death, sticking to the inside of the
syringe or from harvesting the cells post-electrospray, the
sample for chondrocyte differentiation was smaller than the
non-BES mBMSCs. This is demonstrated in the GAPDH
analysis. Given the differences in GAPDH expression and
band intensity for aggrecan and collagen IIa by rt-PCR, the
expression of each chondrocyte marker was normalised to
their relative GAPDH result. This demonstrated mBMSCs
cultured in non-differentiating chondrocyte medium did
not express either aggrecan or collagen IIa for both non-
BES and BES cells. However, mBMSCs exposed to the
chondrocyte differentiation medium showed an increase in
both aggrecan and collagen IIa for the non-BES and BES
mBMSCs (Fig. 6c). It’s suggested that the expression
levels are convincing as both aggrecan and collagen IIa
have shown an increase in expression, indicating chon-
drocyte differentiation occurred, and that the differentia-
tion capability of mBMSC is not adversely affected by this
BES methodology.














MHC class II –
CD117 –
Table demonstrating 13 known surface markers that are either posi-
tively or negatively expressed by mBMSCs, according to guidelines
outlined by the International Society for Cellular Therapy (ISCT)
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Fig. 5 Surface Marker Expression for Bio-Electrosprayed mBMSCs. mBMSCs are characterised by either the expression or absence of known
surface markers. Flow cytometry showed that the a non-BES mBMSCs, represented by pipette cells, and b BES mBMSCs behaved similarly as
they positively and negatively expressed 13 markers associated with mBMSCs. This was illustrated when the cell surface marker represented by
the red line ‘‘shifted’’ to the right of its corresponding isotype or control (black line), indicating a positive expression was determined. However,
if the red line remained either within the black line or ‘‘shifted’’ to the left, this indicated a negative expression and thus the absence of the marker
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Fig. 5 continued
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3.6 Suppression of T-cell Proliferation by Bio-
Electrosprayed mBMSCs
BES mBMSCs were examined for their capacity to sup-
press both autologous and allogeneic proliferation T-cells
[41, 42]. MHC mis-matched splenocytes from BALB/c
(D1) and C57BL/6 (D2) were cultured with both non-BES
and BES mBMSCs, and analysed by CFSE uptake into
replicating DNA after 72 h. In a second study, identical
parameters where implemented with the inclusion of
Concovalin A (ConA) at day 0. This is a mitogen known
for inducing T-cell proliferation, and was used as a positive
control [43]. Although some proliferation was identified for
both studies, significant immunosuppressive capacity for
both non-BES and BES mBMSCs was demonstrated for
alloantigen and mitogen driven proliferation. Statistical
significance was determined by ANOVA analysis
(**p\ 0.01), (***p\ 0.001). Results from these studies
indicated proliferation of T-cells was significantly reduced
in the presence of both non-BES mBMSCs and BES
mBMSCs, with 4-fold proliferation reduction rates
respectively compared to controls as demonstrated Fig. 7a–
c.
3.7 Wound Closure Assay
Studies have shown that MSCs migrate to injury sites and
promote repair through the production of trophic factors,
including growth factors, cytokines, and antioxidants
[44, 45]. We therefore investigated whether the jetting
process would adversely affect the pro-reparative proper-
ties of mBMSCs. For this study, an in vitro wound closure
assay was employed and wound closure was examined
using the A549 lung epithelial cell line. Both non-BES and
BES mBMSCs induced significantly higher rates of wound
closure compared to controls. Wound sizes of 16 ± 2.2%
remained for the non-BES mBMSCs and 15 ± 3.1% for
the BES mBMSCs compared to control wounds. There was
no significant difference between the wounds remaining in
wells treated with non-BES or BES mBMSCs (Fig. 8).
Comparable results were obtained when the BEAS-2B lung
cell line was used as an alternative to A549 in the wound
closure assay (results not shown).
4 Discussion
MSC therapeutic approaches currently involve adminis-
tration via I.V. injection for cell therapies or scaffold
transplantation for tissue engineering and regenerative
medicine purposes. However, major challenges with MSC
entrapment and difficulties with cell-scaffold interactions
have hampered progress with these approaches. Bio-elec-
trospray-mediated delivery where MSCs can be delivered
directly to the target area has potentially several advantages
compared with injection and scaffolds. The aim of this
study was to develop a bio-electrospray methodology that
could be ultimately compatible with in vivo delivery of
MSCs. In previous studies by other groups, high voltages
have been required to generate and maintain a continuous,
stable electrospray of cells. High voltages are not accept-
able therapeutically however because of both patient safety
concerns and reduced MSCs viability and function. Fur-
thermore, these groups have also used ‘‘in-house’’ elec-
trospray apparatuses which means that reproducibility of
experiments between labs is extremely difficult, if not
impossible. In this study, we optimized electrospray
parameters using a commercially available instrument,
Spraybase. Since a large number of parameters affect the
Taylor cone and plume/jet, including environmental con-
ditions such as humidity and temperature, the spray mode
can vary considerable between experiments, and even
within experiments. The presence of a laser/camera visu-
alisation system enabled close monitoring of the Taylor
cone and plume/jet thus allowing the user to fine tune
applied voltage for an optimal spray mode.
As discussed above, low voltages are essential during
bio-electrospraying, both for cell viability and functions
and for translation in vivo. Studies from other groups have
demonstrated that strong external electric fields can nega-
tively impact cells [36–39]. Using Spraybase we suc-
cessfully optimised parameters to enable BES of mBMSCs
at low voltages, ranging between 3 and 6 kV. In agreement
with a previous study by Odenwalder et al., we found that
the ring-shape ground electrode encouraged the spray
bFig. 6 Osteogenic, Adipogenic and Chondrogenic Differeniation of
Bio-Electrosprayed mBMSCs. a shows non-BES and BES mBMSC
which differentiated into bone after 21 days with controls at 910
magnification. This is illustrated by reddish/orange calcium deposits
apparent when stained with Alizarin Red. b shows non-BES and BES
mBMSCs differentiated into fat after 21 days with controls at 910
magnification. This is shown by orange fat deposits when the
differentiated mBMSCs were stained with Oil Red O. Controls
remained undifferentiated when stained with either Alizarin Red
(a) or with Oil Red O (b). c PCR showing expression levels of
aggrecan and collagen IIa, both of which are present in cartilage, after
21 days. (i) Shows expression for aggrecan for both non-BES and
BES mBMSCs. (ii) Shows expression levels for collagen IIa for both
non-BES and BES mBMSCs, and (iii) shows the expression of
GAPDH, a house keeping gene used as a control for comparing of
gene expression data. The presence of these genes indicates that the
BES mBMSCs retained their chondrogenic differentiation potential.
Controls remained undifferentiated, this is shown by the lack of gene
expression. Given the differences in GAPDH expression and band
intensity for aggrecan and collagen IIa by rt-PCR, the expression of
each chondrocyte marker was normalised to their relative GAPDH
result as demonstrated by the mRNA expression graphs
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Fig. 7 Suppression of T-Cell
Proliferation by Bio-
Electrosprayed mBMSCs.
a Represents the induction of
T-cell proliferation when two
mismatched donor mice, i.e.,
BALB/c (D1) and C57/BL6
((D2) were co-cultured together.
The graph clearly shows
significant T-cell suppression
when BES mBMSCs are
introduced indicating the
mBMSCs are affecting T-cell
proliferation. Graph (b) shows
similar results. The introduction
of mitogen Con A suggests a
higher output of T-cell
proliferation, yet when BES
mBMSCs are present, T-cells
are suppressed 4-fold (c)
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droplets to spread [32]. This design of electrode allowed
cells to cover a relatively wide surface area whilst also
making the spray more controllable. However, unlike the
previous study, we successfully achieved a stable jet with a
single needle configuration. Odenwalder et al. suggested
that very high ion concentrations in combination with the
low viscosity of their cell suspensions was the cause of jet
instability in their experiments. As described by other
groups [24, 28], we used solutions with high cell numbers
to overcome the problem of low viscosity. The combina-
tion of the apparatus with high cell numbers and ca-MEM
medium allowed us to reproducibly produce stable sprays
and jets achieved at low voltages using a single extrusion
needle configuration.
Successful electrospray of a number of primary cells,
including various types of stem cells, has been reported
previously [23–28]. However, a full phenotypic analysis of
MSCs post BES has not yet been described [24]. Therefore,
a key part of our study was the analysis of the effect of low
voltage electrospraying on mBMSCs function. In addition
to surface marker expression, multilineage differentiation,
immunosuppressive effects and pro-reparative properties
Fig. 8 Wound Closure using
BES mBMSCs Pro-Reparative
Properties on A549 Cells.
Wound was created and
observed over 24 h for 4
conditions described in 2.8 (n-
3). a Crystal violet staining of
A549 cells show little to no
closure to the wells with
controls. b Plates with
transwells containing either
non-BES or BES mBMSCs
illustrate wound closure. After
20 h, wound was fully closed in
well containing BES mBMSCs).
c Graph demonstrates how
much of the A549 cell wound
was closed by control (ca-MEM
medium only), in relation to
closure with BES mBMSCs. It’s
indicated it’s the presence of
BES mBMSCs which closed the
wound in comparison to the
controls. Graph shows there are
no significant difference
between non-BES mBMSCs
and BES mBMSCs, thus
indicating mBMSCs still retain
their reparative properties after
electrospraying
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were evaluated following BES in vitro. These studies
demonstrated that the jetting methodology did not
adversely affect mBMSCs phenotype or function. To our
knowledge this is the first time such an in-depth analysis of
this methods effects on MSCs specifically, have been
demonstrated. This suggests using BES method to elec-
trospray MSCs to a given target site, has the potential as an
alternative and translational tool for delivering these cells.
MSCs hold great promise as therapeutic entities and as
such are receiving significant levels of attention. By 2016,
MSC therapeutics was estimated to be worth of $8.8 billion
[46]. However, the challenges encountered with current
delivery methods illustrate that new and innovative meth-
ods for MSCs administration are required. The recom-
mended number of cells administrated in cell therapies is
1–2 9 106 MSC/kg [47]. However, due to the aforemen-
tioned problems a substantial number of these cells may be
lost, giving limited success to the various therapies.
Therefore, BES holds potential as a delivery method for
MSCs, and other cell types, as it could enable direct
delivery of known number of cells to a target area in vivo.
This research is based on laboratory apparatus using a
device designed for commercial lab based experimental
studies. Theoretically, using this newly adapted apparatus
and optimised parameters, MSC therapeutics could be used
for any organ through keyhole surgery promoting advances
towards cellular and tissue engineering purposes using a
specially designed medical device. This is a critical step
towards the translation of electrospray technologies for
delivery of cells for therapeutic purposes in vivo.
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